Status:
ACTIVE_NOT_RECRUITING
Cardiovascular Effects of Exercise in Patients With Parkinson's Disease
Lead Sponsor:
Faizan Ahmed
Conditions:
Parkinson Disease
Orthostatic Hypotension
Eligibility:
All Genders
40-90 years
Phase:
NA
Brief Summary
Abnormalities in the regulation of cardiovascular system due to autonomic nervous system (ANS) dysfunction may lead to a sudden decline in blood pressure (BP) upon standing, sitting or performing acti...
Detailed Description
Parkinson's Disease (PD) is associated with abnormal control of the cardiovascular system in up to 50% of patients. The cardiovascular autonomic dysfunction is a result of abnormal regulation of the c...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Parkinson's Disease;
- Between stages 2 and 4 of Hoehn and Yahr classification of Parkinson's Disease;
- Male or female; and
- Age 40-90 years.
Exclusion
- Therapy with anticholinergic, alpha- and beta-adrenergic antagonists or other medication, which could interfere with the regulation of blood pressure and heart rate. These medications are commonly used to treat conditions such as irregular heartbeats, high blood pressure, heart failure, urinary incontinence and other medical conditions (e.g. Alprazolam (Xanax), Amantadine (Symmetrel), Baclofen, Cimetidine, Codeine. Doxazosin, Prazosin, Atenolol (Tenormin), Bisoprolol (Zebeta, also sold as Ziac), Carvedilol (Coreg), Propranolol (Inderal, Inderal LA);
- Clinically significant coronary artery disease;
- Presence of nerve damage in the peripheral nervous system;
- Pregnant or breast feeding females; and
- The presence of failure of other organ systems or diseases that can affect autonomic function or the participant's ability to cooperate. These include dementia, specific tumors, heart failure, hypertension, renal or hepatic disease, severe anemia, alcoholism, hypothyroidism, surgical procedures where the nerves of the sympathetic nervous system have been cut, or cerebrovascular disease.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 28 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03343574
Start Date
December 1 2017
End Date
November 28 2024
Last Update
March 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
London, Ontario, Canada, N6A 5A5